Welcome to our dedicated page for Vita Coco Company SEC filings (Ticker: COCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vita Coco Company, Inc. (NASDAQ: COCO) files reports and disclosures with the U.S. Securities and Exchange Commission as part of its obligations as a public company. This page compiles those SEC filings and pairs them with AI-powered tools that help explain the information contained in key documents.
Through its filings, the company reports on topics such as quarterly and annual financial performance, business developments, and regulatory matters. Recent Form 8-K filings, for example, reference press releases announcing financial results for quarters ended June 30 and September 30, 2025, as well as a company statement regarding tariff relief affecting coconut water products. These filings provide detail on net sales, gross profit, net income, and non-GAAP measures like Adjusted EBITDA, along with management’s commentary on factors such as tariffs, costs, and demand for Vita Coco Coconut Water and related products.
On this page, users can access core documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K as they become available through EDGAR. AI-generated summaries are designed to highlight major themes, clarify technical language, and surface items that may matter to shareholders, such as segment performance, tariff discussions, or capital allocation programs mentioned in earnings releases.
In addition, this page provides convenient access to insider transaction reports on Form 4 and other ownership-related filings when they are filed. Together, these resources allow investors, analysts, and interested readers to review The Vita Coco Company’s regulatory disclosures in one place, with AI assistance to make complex filings easier to understand.
Martin Roper, CEO and Director of Vita Coco Company, Inc. (COCO), reported sales of common stock on 09/12/2025 executed under a Rule 10b5-1 trading plan. The filing shows four sell transactions of 5,000 shares each at weighted-average prices around $40.01, reducing the reporting person's direct beneficial ownership to 352,062 shares. Separate lines show indirect holdings of 286,131 shares held by each of three family trusts and 61,200 shares held by a spouse. The form also discloses multiple fully vested and outstanding non-qualified stock options with various exercise prices and vesting schedules, including options exercisable for 579,670 shares and others vesting through 2035.
Jane Prior, Chief Marketing Officer of Vita Coco Company, Inc. (COCO), reported transactions dated 09/12/2025. She acquired 10,000 shares of common stock by exercising non-qualified stock options at an exercise price of $10.178 per share and simultaneously sold 10,000 shares pursuant to a Rule 10b5-1 trading plan for a weighted average price of $40.002 per share (sales ranged $40.00–$40.03). After these transactions her beneficial ownership is reported as 123,666 shares. The filing lists outstanding non-qualified stock options covering additional shares (totaling ~155,739 underlying shares across multiple grants) with various vesting schedules and exercise prices, several of which are fully vested and exercisable.
Vita Coco Company director Liran Ira reported two securities dispositions on 09/12/2025. The filings show sales of 20,000 and 40,000 shares of common stock executed under a Rule 10b5-1 trading plan, with weighted-average prices reported near $40.00 per share. After the transactions the reporting person is shown as beneficially owning 598,341 shares directly and 742,579 shares indirectly (held by the Ira Liran 2012 Family Trust). The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Jonathan Burth, Chief Operating Officer of Vita Coco Company, Inc. (COCO), reported a sale of 10,000 shares of common stock on 09/12/2025 at a weighted average price of $40.003 under a Rule 10b5-1 trading plan, leaving him with 76,127 shares beneficially owned following the transaction. The Form 4 also discloses multiple outstanding non-qualified stock options with exercise prices ranging from $10.178 to $33.36 and various vesting schedules and exercisability dates. The filing was signed by Alison Klein, Attorney-in-Fact, on 09/16/2025.
Vita Coco Company, Inc. (COCO) filing a Form 144 notifies the proposed sale of 3,000 common shares to be sold through Morgan Stanley Smith Barney on 09/16/2025 on NASDAQ. The shares were acquired the same day by exercise of stock options and paid for in cash.
The filing also discloses multiple recent 10b5-1 sales by Corey Baker totaling 7,000 shares across nine trading dates from 09/05/2025 to 09/15/2025 with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information and includes broker details and share counts but provides no additional context about ownership percentage or intent.
Corey Baker, Chief Financial Officer of Vita Coco Company, Inc. (COCO), reported multiple transactions in common stock and stock options in a Form 4 filing. The filing shows sales of 1,000 shares on 09/11/2025 at $38.66 and on 09/12/2025 and 09/15/2025 at $40.00, and purchases of 1,000 shares on 09/12/2025 and 09/15/2025 at $16.91 under reported transactions. Following these transactions, reported beneficial ownership of common stock moved between 38,754 and 39,754 shares as shown. The filing also discloses several non-qualified stock options with exercise prices ranging from $16.91 to $33.36 and various vesting schedules, with specific vesting and expiration dates noted.
Michael Kirban, Executive Chairman and Director of Vita Coco Company, Inc. (COCO), reported a sale of common stock under a Rule 10b5-1 trading plan. On 09/11/2025 he disposed of 20,000 shares at a weighted average price of $39.045 (individual sale prices ranged from $39.00 to $39.19). After the reported transaction(s) the filing shows 1,579,049 shares beneficially owned indirectly by Mr. Kirban and additional holdings tied to the Michael Kirban Revocable Trust. The filing also discloses outstanding non-qualified stock options totaling 1,164,490 options across multiple grants with exercise prices ranging from $10.178 to $32.78 and varying vesting and expiration schedules. The sale was executed pursuant to a pre-established plan and the Form 4 was signed by an attorney-in-fact on 09/15/2025.
Vita Coco Company, Inc. (COCO) filed a Form 144 reporting insider transactions tied to the sale of common stock. The filing shows 1,000 shares to be sold through Morgan Stanley Smith Barney on 09/15/2025 with an aggregate market value of $39,570. It also discloses a contemporaneous acquisition: the filer exercised options and acquired those 1,000 shares on 09/15/2025 and paid in cash. The filing lists prior 10b5-1 sales by the same person totaling 6,000 shares executed between 09/05/2025 and 09/12/2025 with gross proceeds shown for each trade. The notice includes the required representation that the seller is unaware of undisclosed material adverse information.
Michael Kirban, Executive Chairman and director of The Vita Coco Company, Inc. (COCO), reported insider transactions on Form 4. The filing shows a sale of 30,000 shares of common stock on 09/09/2025 effected pursuant to a Rule 10b5-1 trading plan at a weighted average price of $39.161 per share. The form also records a disposition of 127,629 shares and reports post-transaction beneficial ownership figures including 1,599,049 shares indirectly beneficially owned by Mr. Kirban and 615,681 shares held indirectly by the Michael Kirban Revocable Trust. The filing discloses multiple outstanding non-qualified stock options with exercise prices from $10.178 to $32.78 and vesting schedules through 2036, several of which are fully vested and currently exercisable.
The filing reports insider sales by Corey Baker, Chief Financial Officer of Vita Coco Company, Inc. (COCO). Mr. Baker sold 1,000 shares on 09/09/2025 at $38.40 and 1,000 shares on 09/10/2025 at $38.16 under a Rule 10b5-1 trading plan, reducing his direct common stock holdings from 41,754 to 39,754 shares. The Form 4 also discloses outstanding non-qualified stock options exercisable into a total of 61,197 shares across five option grants with exercise prices ranging from $16.91 to $33.36 and various vesting schedules.